JP2023518390A - ウイルス感染症の治療若しくは予防又はウイルス感染症の発生を制限するための方法及び組成物 - Google Patents

ウイルス感染症の治療若しくは予防又はウイルス感染症の発生を制限するための方法及び組成物 Download PDF

Info

Publication number
JP2023518390A
JP2023518390A JP2022555887A JP2022555887A JP2023518390A JP 2023518390 A JP2023518390 A JP 2023518390A JP 2022555887 A JP2022555887 A JP 2022555887A JP 2022555887 A JP2022555887 A JP 2022555887A JP 2023518390 A JP2023518390 A JP 2023518390A
Authority
JP
Japan
Prior art keywords
composition
viral infection
formula
treating
limiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022555887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518390A5 (https=
Inventor
リー トンプソン，ダリル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Biolife Inc
Original Assignee
Global Biolife Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Biolife Inc filed Critical Global Biolife Inc
Publication of JP2023518390A publication Critical patent/JP2023518390A/ja
Publication of JP2023518390A5 publication Critical patent/JP2023518390A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022555887A 2020-03-16 2021-03-16 ウイルス感染症の治療若しくは予防又はウイルス感染症の発生を制限するための方法及び組成物 Pending JP2023518390A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062990168P 2020-03-16 2020-03-16
US62/990,168 2020-03-16
PCT/US2021/022538 WO2021188520A1 (en) 2020-03-16 2021-03-16 Method and compositions for treating, preventing or limiting the occurrence of viral infection

Publications (2)

Publication Number Publication Date
JP2023518390A true JP2023518390A (ja) 2023-05-01
JP2023518390A5 JP2023518390A5 (https=) 2024-03-27

Family

ID=77768366

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022555887A Pending JP2023518390A (ja) 2020-03-16 2021-03-16 ウイルス感染症の治療若しくは予防又はウイルス感染症の発生を制限するための方法及び組成物

Country Status (9)

Country Link
US (1) US20230132782A1 (https=)
EP (1) EP4121040A4 (https=)
JP (1) JP2023518390A (https=)
KR (1) KR20230012469A (https=)
CN (1) CN115397410A (https=)
AU (1) AU2021236622A1 (https=)
BR (1) BR112022018504A2 (https=)
CA (1) CA3172162A1 (https=)
WO (1) WO2021188520A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230165831A1 (en) * 2021-11-19 2023-06-01 Impact Biolife Science, Inc. Method and composition for rendering cancer cells susceptible to treatment by targeted oncogenetic drivers
CN117462539A (zh) * 2023-12-26 2024-01-30 云南中医药大学 一种二氢黄酮醇型化合物的抗冠状病毒用途及制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090298932A1 (en) * 2008-05-29 2009-12-03 Daryl Lee Thompson Composition and method for the treatment of neurological disorders
WO2019045677A1 (en) * 2017-08-28 2019-03-07 Global Biolife Inc. METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS
JP2019515022A (ja) * 2016-05-16 2019-06-06 グローバル バイオライフ インコーポレーテッドＧｌｏｂａｌ Ｂｉｏｌｉｆｅ Ｉｎｃ． 炎症関連疾患及び障害を治療するための求電子的に強化されたフェノール化合物
US20190365703A1 (en) * 2015-02-13 2019-12-05 Global Biolife Inc. Method and composition for preventing and treating viral infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1605335A (zh) * 2003-05-30 2005-04-13 任启生 含有二氢杨梅素和杨梅素的组合物用于抗病毒等药物
CN101701245B (zh) * 2009-10-21 2013-06-19 中国科学院生物物理研究所 从中药中筛选sars冠状病毒主蛋白酶抑制剂的方法
US20140194500A1 (en) * 2013-01-08 2014-07-10 Kookmin University Industry Academic Cooperation Foundation Methods For Treating of SARS
US12257231B2 (en) * 2015-02-13 2025-03-25 Global Biolife Inc. Method and composition for preventing and treating viral infections
US10966954B2 (en) * 2016-05-16 2021-04-06 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
US10987371B2 (en) * 2017-06-09 2021-04-27 Adaerata, Limited Partnership Methods of preventing or treating filovirus and flavivirus diseases
CN113350330B (zh) * 2020-03-06 2023-04-14 中国科学院上海药物研究所 杨梅素类化合物在制备防治新冠肺炎药物中的应用
CN112546038A (zh) * 2020-11-19 2021-03-26 澳门科技大学 杨梅素在制备预防或治疗冠状病毒、流感病毒的药物中的应用
CN113244217A (zh) * 2021-06-25 2021-08-13 南开大学 二氢杨梅素在制备抑制新冠病毒或肺部纤维化的药物中的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090298932A1 (en) * 2008-05-29 2009-12-03 Daryl Lee Thompson Composition and method for the treatment of neurological disorders
US20190365703A1 (en) * 2015-02-13 2019-12-05 Global Biolife Inc. Method and composition for preventing and treating viral infections
JP2019515022A (ja) * 2016-05-16 2019-06-06 グローバル バイオライフ インコーポレーテッドＧｌｏｂａｌ Ｂｉｏｌｉｆｅ Ｉｎｃ． 炎症関連疾患及び障害を治療するための求電子的に強化されたフェノール化合物
WO2019045677A1 (en) * 2017-08-28 2019-03-07 Global Biolife Inc. METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Citrus fruits are rich in flavonoids for immunoregulation and potential targeting ACE2", PREPRINTS, JPN6025008603, 23 February 2020 (2020-02-23), pages 1 - 13, ISSN: 0005677600 *
"Potential Natural Compounds for Preventing SARS-CoV-2 (2019-nCoV) Infection", PREPRINTS, JPN6025008602, 10 March 2020 (2020-03-10), pages 1 - 17, ISSN: 0005677601 *

Also Published As

Publication number Publication date
CA3172162A1 (en) 2021-09-23
BR112022018504A2 (pt) 2022-11-29
WO2021188520A1 (en) 2021-09-23
US20230132782A1 (en) 2023-05-04
KR20230012469A (ko) 2023-01-26
CN115397410A (zh) 2022-11-25
AU2021236622A1 (en) 2022-10-13
EP4121040A4 (en) 2024-07-17
EP4121040A1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
Yousefi et al. A global treatments for coronaviruses including COVID‐19
McKee et al. Candidate drugs against SARS-CoV-2 and COVID-19
JP2023526836A5 (https=)
US6410570B1 (en) Methods of inactivating a virus and controlling viral replication
Smee et al. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses
US20090304630A1 (en) Treating severe and acute viral infections
EA020283B1 (ru) Средство для профилактики и лечения высокопатогенных инфекционных заболеваний
WO2021023264A1 (zh) 用于治疗非洲猪瘟的药物组合物及其用途
CN118384167B (zh) 巴洛沙韦钠在治疗克里米亚-刚果出血热病毒感染方面的应用
CN115666572A (zh) 用于预防或治疗流行性rna病毒传染病的药物组合物
AU2008266910A1 (en) Early intervention of viral infections with immune activators
JP2023518390A (ja) ウイルス感染症の治療若しくは予防又はウイルス感染症の発生を制限するための方法及び組成物
Pavlova et al. A review on the mechanism of action of favipiravir and hydroxychloroquine in COVID-19
JP2023528561A5 (https=)
Gowen et al. Combinatorial ribavirin and interferon alfacon-1 therapy of acute arenaviral disease in hamsters
Dianzani et al. Nonspecific defenses
WO2022015198A1 (ru) Вакцина и способ защиты от коронавирусной инфекции
JPWO2003035052A1 (ja) ウイルス感染予防・治療剤
Wutzler et al. Neuraminidase inhibitors in the treatment of influenza A and B–overview and case reports
JP2011502168A (ja) ウイルス感染の阻害方法
CN108014129A (zh) 铁离子在抑制rna病毒中的应用
JP2011500830A (ja) ウイルス感染を阻害する方法
US12171732B2 (en) Compositions and use of N-chlorotaurine for treatment and prevention of respiratory infections
EP4431103A1 (en) Formulations comprising heparan sulfate for the treatment and prevention of viral infections caused by orthocoronaviridae
CN121774965A (zh) 一种靶向csde1相分离的化合物及其在抗病毒中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240314

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250902